Flare of adult-onset Still’s disease following mRNA COVID-19 vaccination: a case report and review of literature

Ji-Won Kim · Ju-Yang Jung · Chang-Hee Suh · Hyoun-Ah Kim

Received: 24 December 2021 / Revised: 2 February 2022 / Accepted: 15 February 2022 / Published online: 19 February 2022 © International League of Associations for Rheumatology (ILAR) 2022

Abstract
The upheaval caused by the coronavirus disease 2019 (COVID-19) pandemic has allowed to large population to use new vaccines urgently. Although vaccine development programs and available epidemiological data reassure us, there are concerns about specific risks associated with vaccinations in patients with autoimmune-autoinflammatory diseases. These patients have the potential to decrease humoral and cellular immune responses caused by biologic agents and develop an acute flare of underlying disease following vaccination. We herein present a rare case of a 49-year-old female with a flare of adult-onset Still’s disease (AOSD) after the first dose of BNT162b2 mRNA COVID-19 vaccination. She had been diagnosed with AOSD 7 years earlier and had achieved remission with tocilizumab. This patient came to the emergency room with fever and nausea that occurred 4 days after the first vaccination. Based on laboratory results and clinical manifestations, we suspected AOSD flare and was treated with steroid pulse therapy. In this report, we also discuss possible mechanisms linking vaccination with a flare of AOSD. Considering the close time relationship between COVID-19 vaccinations and a flare of AOSD, physicians should be aware of adverse events from this new vaccination and evaluate the benefits and risks of vaccination for each patient.

Key Point
• COVID-19 vaccination may cause an AOSD flare in patients who are in remission with tocilizumab.

Keywords Adult-onset Still’s disease · Biologic agent · COVID-19 vaccination · Disease activity · Flare

Introduction
The upheaval caused by the coronavirus disease 2019 (COVID-19) pandemic has raised the need for effective vaccines worldwide and therefore enabled vaccine use within 1 year of the emergence of the new virus [1]. Urgent use of vaccines to form herd immunity before the collapse of public health and the global economy has been authorized to large populations [2]. The safety, immunogenicity, and efficacy of the vaccine have been extensively studied through computer simulations, animal experiments, and human clinical trials [3]. However, establishing safety for all subgroups, including those with underlying diseases and young ages, remains a challenge to be solved [4]. Among those with underlying diseases, particularly in patients with autoimmune-autoinflammatory diseases (AIAIDs), may have specific risk and benefit profiles for vaccines. Given both the pathogenic mechanisms of immunological diseases and the immuno-suppressive agents used in treatment, COVID-19 vaccination requires special consideration to such patients [5].

An increasing number of biologic therapies are being investigated and approved for treatment of various AIAIDs.
The development of biologic therapies includes monoclonal antibodies targeting cytokines such as tumor necrosis factors (TNF) or interleukins (IL) and new novel small molecules which inhibit signal transduction via the intracellular pathways of inflammation [6]. Although guidelines have been proposed to recommend vaccination for patients with AIAIDs on these biologic agents, the impact of the vaccine is still controversial and relevant safety data are scarce [7, 8]. There are two main concerns regarding COVID-19 vaccination in patients with AIAIDs: the concerns about decreased humoral and cellular immune response caused by biologic agents and the potential to develop an acute flare of underlying disease. Cases related to the latter concern have also been reported in several AIAIDs [9].

Here, we report the case of a patient who developed a flare of adult-onset Still’s disease (AOSD) who maintained remission with tocilizumab after her first vaccination with BNT162b2 mRNA COVID-19 vaccine (Pfizer, Inc., and BioNTech).

Case description

A 49-year-old woman was first diagnosed with AOSD at the age of 42 years, when she presented with an evanescent skin rash, fever, liver enzyme elevation, hepatosplenomegaly, and arthritis. Tests for rheumatoid factor and antinuclear antibodies were negative. She was admitted to the hospital after 5 flare-ups a year with symptoms of fever, arthritis, and evanescent skin rash, despite aggressive therapy that included high levels of prednisolone (60 mg/day), methotrexate (MTX) (15 mg/week), cyclosporine (100 mg/day), and azathioprine (100 mg/day). She was refractory to corticosteroid therapy, MTX, and azathioprine; therefore, monthly infusions of tocilizumab (TCZ; 400 mg) were initiated for 12 months after the diagnosis of AOSD.

This treatment appeared to be effective for 76 months, without any flares, until she presented to our emergency ward with complaints of mild fever, nausea, and myalgia that had persisted for 16 days. These symptoms developed 4 days after the first dose of the mRNA COVID-19 vaccine, and 1 week before the emergency room visit, TCZ was administered as scheduled and prednisolone (30 mg/day) increased to moderate dose, but the symptoms persisted. On admission, her vitals were within normal ranges. The laboratory data were as follows: white blood cell count, 7900 per mm$^3$ (76% neutrophils and 16% lymphocytes) (reference, 3400–10,600 per mm$^3$); hemoglobin level, 7.9 g/dL (reference, 10.7–15.3 g/dL); erythrocyte sedimentation rate (ESR), 2 mm/h (reference, 0–25 mm/h); C-reactive protein (CRP), 0.06 mg/dL (reference, 0–0.5 mg/dL); lactate dehydrogenase (LDH), 1499 U/L (reference, 100–200 U/L); and ferritin, 27,586 ng/mL (13–150 ng/mL). Anti-nuclear antibody and rheumatoid factor were negative. Blood cultures, urine analysis, and real-time polymerase chain reaction test for COVID-19 were all negative. No specific abnormalities were found on chest and abdominal computed tomography. Infection and malignancies were excluded by clinical evaluation, laboratory, and radiologic findings. Based on these results, we found that her symptoms were attributed to an AOSD flare after vaccination. Despite increased steroid administration, high-spiking quotidian fever, hemoglobin decrease, and ferritin elevation worsened, she was immediately administered IV corticosteroids (methylprednisolone 500 mg) for 3 days. Immediately after steroid treatment, her hemoglobin level and other laboratory findings recovered (Fig. 1). The prednisolone dose was maintained at 30 mg/day for a further 2 weeks. After that, she received infusions of TCZ (400 mg) by reducing prednisolone to 20 mg/day and maintained TCZ (400 mg) IV at monthly intervals with MTX (10 mg/week) while gradually reduced prednisolone dose.

Search strategy

A systemic search of the publication literature on the electronic bases Medline/PubMed, Scopus, and EMBASE was conducted using the following keywords: “COVID-19 vaccination,” “SARS-CoV-2 vaccination,” “adult-onset Still’s disease,” “flare-up,” “relapse,” “autoinflammatory disease,” “tocilizumab,” also including their abbreviations. Our literature review was searched from November 2019, when it is estimated that COVID-19 first occurred, and was last updated on November 1. Each article was analyzed to identify eligibility criteria and their relevance to this study. We included only the case reports for adult patients written in English. The exclusion criteria included publications of reviews, letters, or abstracts only; and different languages other than English. The flowchart of the study selection process is shown in Fig. 2. After excluding non-relevant papers and duplicates, fourteen articles met our searching inclusion criteria: two cases of AOSD flare-up after COVID-19 vaccination (Table 1), six cases of new-onset of AOSD after COVID-19 vaccination (Table 2), and six cases of new-onset flare-up of AOSD after other vaccinations (Table 3).

Discussion

AOSD is a systemic auto-inflammatory disorder of unknown etiology characterized by high spiking fever, arthritis, an evanescent salmon-colored rash, and laboratory abnormalities including leucocytosis, high serum ferritin levels, elevated liver enzymes, and elevated acute phase reactants (APRs) such as ESR and CRP [23]. The pathogenesis of AOSD remains unclear; however, dysregulation of the inflammasome complex with overproduction of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6, IL-18,
Fig. 1 Changes of laboratory findings according to treatments and vaccination. Hemoglobin levels were declined significantly after first vaccination with mRNA coronavirus disease 2019 (COVID-19) vaccine.

Fig. 2 Flowchart of the study selection process.
and interferon-γ) appears to play a pivotal role [24]. Treatment using biologics targeting these cytokines, such as the IL-6 receptor antagonist TCZ and IL-1 receptor antagonist anakinra, has become an attractive therapeutic option in the recent years [25].

In the COVID-19 era, the role of inflammatory cytokines in the balance between virus clearance and hyperinflammation mediating severe diseases is being highlighted. Uncontrolled and increased release of pro-inflammatory cytokines and impairment of virus clearance led to cytokine storms, creating a background for severe COVID-19 [26]. Macrophage activation syndrome along with hyperferritinemia and fever, which are induced in severe COVID-19 courses, shares striking features of the cytokine storm-associated mechanisms in AOSD, suggesting that COVID-19 and AOSD have similar clinical and laboratory findings [27–29]. Indeed, evidence of a similar role in the highly efficient treatment for AOSD targeting interleukin is increasing in COVID-19 hyperinflammation [30]. Cytokine modulators were evaluated in clinical trials for COVID-19, and TCZ, an IL-6 inhibitor, is used as one of the options for cytokine storm treatment that causes multiple organ damage and death during COVID-19 [31, 32]. Recently, there was a case of treatment with the IL-1 receptor antagonist anakinra in a patient diagnosed with AOSD after recovering from a COVID-19 [33].

There have been some case reports in which a misdirected immune response against COVID-19 triggered the onset of AOSD [33, 34]. Theoretically, an innovative vaccine of COVID-19 may behave like an adjuvant, resulting in perturbations in immune system, acting as a potential trigger for AOSD. As of concern, several cases of flares of other AIAIDs [9, 35] or new diagnoses of AOSD due to COVID-19 vaccination have been reported [12–16]. On the other hand, to the best of our knowledge, there have been only two cases of flare up of AOSD reported following COVID-19 vaccination [10, 11]. There was one case of flare of AOSD after the second dose of COVID-19 mRNA vaccine was reported in Japan [10]. This patient had repeated remissions and relapses of AOSD but was relieved with low dose of steroids and achieved drug-free remission status over the past 2 years before vaccination, and improved symptoms by treating with TCZ for a flare that occurred after vaccination. In another case, AOSD flared after the first dose of ChAdOx1 nCoV-19 vaccination while maintaining low disease activity of AOSD with etanercept, and symptoms significantly improved as etanercept was change to TCZ [11].

Contrary to the reported cases in which flare up of AOSD was treated with TCZ, it is noteworthy that in our case, AOSD was flared even though TCZ was administered 10 days after the first dose of vaccination. Unlike other biologic agents that decrease the humoral response to vaccines, TCZ induces a strong anti-inflammatory response while sustaining the protective humoral response; thus, it is not recommended to adjust the administration schedule according to COVID-19 vaccination, and our patient received TCZ as scheduled [36]. Given the close temporal relationship between vaccination and onset of symptoms despite TCZ preventing the cytokine storm and ruling out other infections and malignancies, we concluded that vaccination against COVID-19 may have triggered the occurrence of flare of AOSD.

Table 1 Cases of disease flare of AOSD after COVID-19 vaccination

| Sex/age | AOSD duration | Type of vaccine/manufacture | Symptom onset time after vaccination | Presenting symptoms | Relevant laboratory results | Treatment before event | Treatment for flare | Country [Ref] |
|---------|---------------|-----------------------------|--------------------------------------|---------------------|---------------------------|------------------------|---------------------|---------------|
| F/37    | 13 years      | mRNA vaccine/BNT162b2 (Pfizer) | A few days after the second dose     | High-grade fever, Salmon-pink eruption, Polyarthritis, Sore throat | Elevated CRP and LDH, Negative RF and ANA, Lymphadenopathy on CT | A drug-free remission status for the previous 2 years | Tocilizumab subcutaneously at 162 mg/m² weeks | Japan [10] |
| F/34    | 22 years      | Viral vector vaccine/ChAdOx1 nCoV-19 | 7 days after the first dose         | High-grade fever, Salmon-pink eruption, Sore throat, Pleuritic chest pain | Leukocytosis with elevated CRP and ESR, High serum ferritin, Negative ANA, Minimal pericardial effusion | Low disease activity with etanercept and low-dose glucocorticoid for 14 years | Methylprednisolone pulse 125 mg for 3 days, Tocilizumab 8 mg/kg every 2 weeks for 2 months | South Korea [11] |

AOSD adult-onset Still’s disease, COVID-19 coronavirus disease 2019, Ref reference, mRNA messenger ribonucleic acid, CRP C-reactive protein, LDH lactated dehydrogenase, RF rheumatoid factor, ANA anti-nuclear antibody, CT computed tomography, SC subcutaneous
The mechanisms underlying AOSD flare-ups after vaccination have not yet been elucidated. A possible pathologic mechanism is that mRNA transcribes into spike glycoproteins after inoculation, and these proteins are displayed on antigen-presenting cells by molecular mimicry, leading to an acute immune response [37]. Another potential cause is that the mRNA vaccine acts as an adjuvant and stimulates innate immunity through endosomal and cytoplasmic immune receptors, such as toll-like receptors [38]. Moreover, one published data showed that BNT162b2 mRNA vaccines may induce a significant increase in IL-6, IL-15, and interferon-γ, which play an important role in the pathogenesis of AOSD [39]. We hypothesized that the occurrence of this event in our patient who was being treated with IL-6 inhibitor resulted in a flare of AOSD due to activation of cytokines other than IL-6 following the vaccination.

In this particular case, there are two main emphases on COVID-19 vaccination in patients with AOSD. First, the occurrence of a new-onset of AOSD after COVID-19 vaccination should be considered in patients with AOSD. Second, the use of IL-6 inhibitors in the treatment of AOSD should be carefully considered in the context of COVID-19 vaccination.

### Table 2: Cases of new-onset of AOSD after COVID-19 vaccination

| Sex/age | Type of vaccine/manufacturer | Symptom onset time after vaccination | Presenting symptoms | Relevant laboratory results | Treatment for AOSD | Country [Ref] |
|---------|------------------------------|-------------------------------------|---------------------|---------------------------|-------------------|--------------|
| M/36    | Viral vector vaccine/ChAdOx1 nCoV-19 | 4 days after the first dose | High-grade fever Evanescent rash Chest pain | Leukocytosis with elevated CRP and ESR High serum ferritin | Methylprednisolone 1 mg/kg IL-1 receptor antagonist anakinra (100 mg daily) | Italy [12] |
| M/22    | mRNA vaccine/BNT162b2 (Pfizer) | 13 days after the first dose | High-grade fever Chest pain Maculo-papular eruption Arthritis | ST elevation on ECG High serum ferritin | Methylprednisolone pulse 1 g for 3 days IV immunoglobulins 2 g/kg IL-1 receptor antagonist anakinra (100 mg daily) | Romania [13] |
| M/43    | mRNA vaccine/BNT162b2 (Pfizer) | 10 days after the second dose | High-grade fever Macular rash Arthritis Sore throat | Leukocytosis with elevated CRP Increased LDH Bilateral pleural effusion Negative RF and ANA | Methylprednisolone pulse 1 g for 3 days | Israel [14] |
| F/56    | mRNA vaccine/BNT162b2 (Pfizer) | 7 days after the second dose | High-grade fever Arthritis Sore throat Chest pain | Leukocytosis with elevated CRP High serum ferritin Increase liver enzymes Negative RF and ANA | Methylprednisolone 1 mg/kg | Israel [14] |
| F/45    | mRNA vaccine/mRNA-1273 (Moderna) | 5 days after the second dose | High-grade fever Sore throat Myalgia | Leukocytosis with elevated CRP and ESR Elevated cardiac biomarkers Lymphadenopathy on CT Bilateral infiltrates on chest X-ray | Methylprednisolone 1 mg/kg | USA [15] |
| F/36    | mRNA vaccine/BNT162b2 (Pfizer) | 10 days after the first dose | High-grade fever Sore throat Arthritis | Leukocytosis with elevated CRP and ESR Splenomegaly and lymphadenopathy on CT Negative RF and ANA | Methylprednisolone pulse 1 g for 3 days Tocilizumab 8 mg/kg IV | South Korea [16] |

AOSD adult-onset Still’s disease, COVID-19 coronavirus disease 2019, Ref reference, CRP C-reactive protein, ESR erythrocyte sedimentation rate, IL interleukin, mRNA messenger ribonucleic acid, ECG electrocardiogram, IV intravenous, LDH lactated dehydrogenase, RF rheumatoid factor, ANA anti-nuclear antibody, CT computed tomography
regarding patients with TCZ-induced remission in refractory AOSD, it is necessary to consider an AOSD flare even if APRs are within the nearly normal range in the presence of suspected disease-triggering factors [40]. Since TCZ blocks IL-6, which is the major inducer of APRs, there may be no changes in APRs, as in this case. Therefore, other laboratory tests such as ferritin, LDH, WBC, and hemoglobin as well as the clinical features would play a major role in diagnosing AOSD flare in patients using TCZ. Second, COVID-19 vaccinations can cause new-onset AOSD and flares in patients in remission. There is a possibility of flare-up of the underlying disease due to the vaccination even in a long-term remission by maintaining the biologic agents, and similar situations may occur, especially in TCZ, which is also used as a treatment for COVID-19.

Although not all cases will be reported, COVID-19 vaccination induced new-onset or flare of AOSD cases are very low, given that nearly 40% of the world’s population is fully vaccinated [41]. Fortunately, new-onset or flare of AOSD due to broadly used vaccines such as influenza, pneumococcal, and hepatitis vaccines were also rare [17–22]. In addition, a prospective cohort study has also been published that COVID-19 vaccine does not increase the risk of disease flare-ups in patients with autoimmune diseases [42]. The largest study reported on the use of viral vectors or mRNA vaccines in patients with AIAIDs on anti-IL-1/6 biologics also showed no serious concerns, such as hospital admissions and deaths, about COVID-19 vaccination [43]. However, the occurrence of hyperinflammation such as AOSD after any vaccinations, including COVID-19, should be recognized as a very rare possibility, as it can lead to life-threatening complications if treatment is not initiated immediately.

In conclusion, it is noteworthy that this patient is the first to report the development of AOSD flare after receiving the first dose of mRNA COVID-19 vaccinations. In addition, this is the first experience of disease flare in a patient with rheumatic diseases receiving TCZ. Although AOSD flares are rare and benefits of vaccinations outweigh the relatively small risks, physicians should inform patients of possible adverse effects from vaccinations, such as flare and should monitor them carefully to assist with worsening underlying diseases.

Acknowledgements This article was reviewed by English editing service, Editage http://www.editage.co.kr.

Author contribution JWK, JYJ, CHS, and HAK contributed to the case presentation, data collection, and interpretation. JWK and HAK contributed to write the manuscript. All authors revised the manuscript and gave final approval for submission.

Data availability All available data are reported in the manuscript.

Code availability Not applicable

Disclosures None.

References
1. Silveira MM, Moreira GMSG, Mendonça M (2021) DNA vaccines against COVID-19: perspectives and challenges. Life Sci 267:118919
2. van Riel D, de Wit E (2020) Next-generation vaccine platforms for COVID-19. Nat Mater 19:810–812
3. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A (2020) [Comment] COVID-19 vaccine safety. Int J Mol Med 46:1599–1602
4. Soleimanpour S, Yaghoubi A (2021) COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines 20:23–44
5. Rodríguez Y, Novelli L, Rojas M et al (2020) Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmunity 114:102506

Table 3 New onset or flare-up of AOSD after several vaccinations

| Sex/age | Pre-vaccine history of AIAIDs or comorbidities | New onset or flare-up | Type of vaccine | Symptom onset time after vaccination | Country [Ref] |
|---------|-----------------------------------------------|------------------------|-----------------|--------------------------------------|---------------|
| M/66    | No                                            | New onset              | 23-valent pneumococcal polysaccharide vaccine | 1 week after receiving vaccine | Israel [17]   |
| F/73    | No                                            | New onset              | Influenza       | 2 days after receiving vaccine       | South Korea [18] |
| F/61    | No                                            | New onset              | Influenza       | NA                                   | Japan [19]    |
| F/20    | No                                            | New onset              | Influenza       | 1 week after receiving vaccine       | Thailand [20] |
| F/66    | No                                            | New onset and flare-up | Influenza       | 1 week after receiving vaccine       | Japan [21]    |
| F/38    | No                                            | New onset              | Hepatitis A and B vaccination | 10 days after receiving vaccine | France [22]   |

AOSD adult-onset Still’s disease, AIAIDs autoimmune-autoinflammatory diseases, Ref reference, NA not available
20. Soj M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39:2085–2094

21. Roy RK, Sharma U, Wasson MK, Jain A, Hassan MI, Prakash H (2021) Macrophage activation syndrome and COVID-19: impact of MAPK driven immune-epigenetic programming by SARS-CoV-2. Front Immunol 12:763313

22. Misra DP, Agarwal V, Gasparian AY, Zimba O (2020) Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39:2055–2062

23. Meng J, Ma Y, Jia J et al (2020) Cytokine storm in coronavirus disease 2019 and adult-onset Still’s disease: similarities and differences. Front Immunol 11:603389. https://doi.org/10.3389/fimmu.2020.603389

24. Colafrancesco S, Alessandri C, Conti F, Priori R (2020) COVID-19 gone bad: a new character in the spectrum of the hyperferri-tinemic syndrome? Autoimmun Rev 19:102573. https://doi.org/10.1016/j.autrev.2020.102573

25. Rabaan AA, Al-Ahmed SH, Muhammad J et al (2021) Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines (Basel) 9:436. https://doi.org/10.3390/vaccines9050436

26. Coomes EA, Haghbayan H (2020) Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol 30:1–9

27. Bamidis AD, Koehler P, di Cristanziano V et al (2021) First manifestation of adult-onset Still’s disease after COVID-19. Lancet Rheumatol 3:e319–e321

28. Alshahlan A, Jabbad R, Tayeb S et al (2021) Diagnosis of adult-onset Still’s disease in a patient who has recovered from Coronavirus-19. Clin Med Insights Case Rep 14:1179547621996306

29. Baimakhamedov C, Makhmudov S, Botabekova A (2021) Sero-positive rheumatoid arthritis after vaccination against SARS-CoV-2 infection. Int J Rheum Dis 24:1440–1441

30. Park JK, Lee EB, Shin K et al. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: clinical guidance of the Korean College of Rheumatology. J Korean Med Sci 36:e95.

31. Vojdani A, Kharrazian D (2020) Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol 217:108480

32. Park JW, Lagniton PNP, Liu Y, Xu RH (2021) mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 17:1446–1460

33. Bergamaschi C, Terpos E, Rosati M et al (2021) Systemic IL-15, IFN-γ, and IFP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep 36:109504

34. Gauldie J, Richards C, Harnish D, Landsorp P, Baumann H (1987) Interferon beta 2B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 84:7251–7255

35. Ritchie H, Mathieu E, Rodès-Guirao L, et al (2020) Coronavirus pandemic (COVID-19). Published online at OurWorldData.org. https://ourworldindata.org/covid-vaccinations. [Online Resource]

36. Pinte L, Negoi F, Ionescu GD et al (2021) COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases. J Pers Med 11:1283

37. Peet CJ, Papadopoulou C, Sombrindo BRM, Wood MR, Lachmann HJ (2021) COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics. Rheumatol Adv Pract 5:rab043. https://doi.org/10.1093/rhap/rab043

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.